Comment: Novelis-Aleris EU decision brings new theory of harm: ‘pivotality’
Novelis was hamstrung in the 2019 EU review of its Aleris acquisition by a new theory of harm focusing on “pivotality” to assess capacity constraints, according to the decision published last...To view the full article, register now.
Already a subscriber? Click here to view full article